|

The Spotlight Round Up Video, March 17th

BySarah Abelsohn
psychedelic-spotlight-roundup-video1

As we continue to strive to be the leading source for news and unique perspective within the emerging sector of medicinal psychedelics, we are excited to debut the Spotlight Roundup! This video series, produced in collaboration with Elk’s Pride Pictures, provides a concise and informative roundup related to some of the most important news developments happening within this rapidly expanding industry. From the latest IPO’s, to new clinical trials, the Spotlight Roundup covers everything you need to know!

Similar Posts

  • This Week in Psychedelic Stocks [UPDATES ON MINDMED (MMED/MMEDF) CMPS, NUMI & ATAI, CYBIN]

    Listen, Videos

    In today’s episode of “This Week in Psychedelic Stocks”, we’ll see some news on MindMed (MMED / MMEDF/MMQ), Compass Pathways (CMPS), Atai Life Sciences, Numinus Wellness (NUMI), Cybin.

    We will cover the latest developments in the field writ large.
    This means we will cover any stories that affect the all the companies in this field, as well as company specific developments.

    Timestamps:
    0:00 – Intro
    0:32 – Norway Decriminalization Bill
    1:59 – Psychedelic Market Stats
    3:21 – Magic Mushrooms to Treat Obesity
    5:40 – Ketamine to Treat Suicidal Thoughts?
    7:09 -The Acid King?
    8:58 – MindMed (MMED/MMEDF/MMQ) Updates
    10:04 – Compass Pathways (CMPS) Updates
    11:44 – Atai Life Sciences Updates
    14:02 – Numinus (NUMI) Updates
    15:13 – CYBIN Updates

    So this is it for This Week in Psychedelic Stocks fellow psychedelic investors!

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #PsychedelicStocks

  • MindMed Raises $19.5 Million // What Does This Mean for MMEDF/MMED? [Plus Upcoming Market CRASH?]

    Listen, Videos

    Hey guys! Today’s episode is more of a fast rant on the recent press release about MindMed raising ANOTHER $19.5M from Canaccord Genuity Corp, on a deal that is set to close tomorrow, March 9th.
    Here, I’m discussing:
    1. The number MindMed shares being sold and their respective price;
    2.Why is MindMed doing this?
    3. Potential short term and long term effects on MMED’s stock price
    4. Nasdaq uplisting?
    5. Market crash thoughts

    I hope you guys found some value in this and I’ll keep you posted for more changes!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌
    Instagram: @psychedelicinvestor

    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    #MindMed​​ ​#MindmedStock​​ #MMEDNews

  • Atai Life Sciences IPOing TOMORROW ( Is Atai a BUY?)

    Listen, Videos

    ATAI IPOS TOMORROW! It’s finally happening! This Friday, on June 18th, 2021, the company I’ve been talking about for a while now, Atai Life Sciences, is set to IPO on the NASDAQ stock exchange, under ticker symbol “atai”.

    This will automatically make Atai a runner for the title of the most advanced public psychedelic medicines company on the market.

    So in this episode, we’ll discuss several things:

    1. The details of the IPO
    2. We’ll take a look at their financials
    3. Look at Atai Life Sciences’ investment thesis
    4. What I will be doing

    Enjoy the episode!

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!
    Follow us on social media! 🙌

    Instagram: @psychedelicinvestor
    Email: thepsychedelicinvestor@gmail.com
    Website: https://thepsychedelicinvestor.com/
    editing: @themyaholy
    Facebook: @thepsychedelicinvestor
    Music: www.bensound.com
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor
    https://www.atai.life/

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #Atai #AtaiLifeSciences #AtaiIPO

  • MindMed vs. atai Life Sciences (Everything You Need to Know Before Buying MNMD / MMED/ ATAI)

    Listen, Videos

    THE MINDMED VS. ATAI discussion you need to hear!

    Prior to atai’s IPO on the NASDAQ stock exchange, we repeatedly said that when atai Life Sciences goes public, the company will become MindMed ‘s ( MNMD: NASDAQ) (MMED: NEO) top competitor.

    Well, atai did IPO on June 18 under ticker symbol “atai”. For this reason, I invited Jason Najum from Microdose.buzz to have a conversation. In this episode, we have a general discussion about:

    – MindMed’s flagship programs and the different businesses and programs ran under atai’s umbrella.
    – The companies’ financial capability to run clinical trials.
    -MindMed’s and atai’s potential to disrupt the way we treat mental illness within the next 5 to 10 years.
    – Potential return on investment for retail investors.

    Time Stamps:
    0:00 – Intro
    4:11 – What is atai’s mission?
    6:24 – What is MindMed’s Mission
    8:29 – atai’s clinical trial pipeline
    19:45 – MindMed’s clinical trial pipeline
    24:25 – How do MindMed and atai differ in business structure?
    30:40 – Comparing the financials

    Remember to Like, Subscribe, and SMASH that notifications bell to keep up to date on all the latest Psychedelic Stocks news!

    Enjoy the episode!

    Check out Jason’s writing at:
    https://microdose.buzz/

    Follow us on social media! 🙌
    Instagram: @thepsychedelicinvestor
    Facebook: @thepsychedelicinvestor

    Want to collaborate? Send us an email at:
    thepsychedelicinvestor@gmail.com

    Website: https://thepsychedelicinvestor.com/

    Music from:
    www.bensound.com

    Video editing: @themyaholy

    Check out our Benziga discounts
    https://benzinga.grsm.io/jameshallifax1834
    https://benzinga.grsm.io/thepsychedelicinvestor

    DISCLAIMER: I am not a financial adviser nor a CPA. These videos are for educational and entertainment purposes only. Investing of any kind involves risk. While it is possible to minimize risk, your investments are solely your responsibility. It is imperative that you conduct your own research. I am merely sharing my opinion with no guarantee of gains or losses on investments.

    All of the information in this video is public information that James (The Psychedelic Investor) believes to be reliable but it is not guaranteed to be 100% accurate and as such should not be used as advice. Any opinions or thoughts from James (The Psychedelic Investor) are subject to change.

    #MindMed #MNMD #Atai